Literature DB >> 29040754

Development of unique cytotoxic chimeric antigen receptors based on human scFv targeting B7H6.

Casey K Hua1,2, Albert T Gacerez2,3, Charles L Sentman2,3, Margaret E Ackerman1,2.   

Abstract

As a stress-inducible natural killer (NK) cell ligand, B7H6 plays a role in innate tumor immunosurveillance and is a fairly tumor selective marker expressed on a variety of solid and hematologic cancer cells. Here, we describe the isolation and characterization of a new family of single chain fragment variable (scFv) molecules targeting the human B7H6 ligand. Through directed evolution of a yeast surface displayed non-immune human-derived scFv library, eight candidates comprising a single family of clones differing by up to four amino acid mutations and exhibiting nM avidities for soluble B7H6-Ig were isolated. A representative clone re-formatted as an scFv-CH1-Fc molecule demonstrated specific binding to both B7H6-Ig and native membrane-bound B7H6 on tumor cell lines with a binding avidity comparable to the previously characterized B7H6-targeting antibody, TZ47. Furthermore, these clones recognized an epitope distinct from that of TZ47 and the natural NK cell ligand NKp30, and demonstrated specific activity against B7H6-expressing tumor cells when expressed as a chimeric antigen receptor (CAR) in T cells.
© The Author 2017. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Antibody; B7H6; cancer; chimeric antigen receptor; immunotherapy; single chain fragment variable

Mesh:

Substances:

Year:  2017        PMID: 29040754      PMCID: PMC5914360          DOI: 10.1093/protein/gzx051

Source DB:  PubMed          Journal:  Protein Eng Des Sel        ISSN: 1741-0126            Impact factor:   1.650


  38 in total

1.  The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions.

Authors:  Fiona A Harding; Marcia M Stickler; Jennifer Razo; Robert B DuBridge
Journal:  MAbs       Date:  2010-05-01       Impact factor: 5.857

2.  Flow-cytometric isolation of human antibodies from a nonimmune Saccharomyces cerevisiae surface display library.

Authors:  Michael J Feldhaus; Robert W Siegel; Lee K Opresko; James R Coleman; Jane M Weaver Feldhaus; Yik A Yeung; Jennifer R Cochran; Peter Heinzelman; David Colby; Jeffrey Swers; Christilyn Graff; H Steven Wiley; K Dane Wittrup
Journal:  Nat Biotechnol       Date:  2003-01-21       Impact factor: 54.908

3.  Highly avid magnetic bead capture: an efficient selection method for de novo protein engineering utilizing yeast surface display.

Authors:  Margaret Ackerman; David Levary; Gabriel Tobon; Benjamin Hackel; Kelly Davis Orcutt; K Dane Wittrup
Journal:  Biotechnol Prog       Date:  2009 May-Jun

Review 4.  Molecular engineering and design of therapeutic antibodies.

Authors:  Leonard G Presta
Journal:  Curr Opin Immunol       Date:  2008-08       Impact factor: 7.486

5.  Deimmunization of monoclonal antibodies.

Authors:  Tim D Jones; Laura J Crompton; Frank J Carr; Matthew P Baker
Journal:  Methods Mol Biol       Date:  2009

6.  Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.

Authors:  Yili Li; Qian Wang; Roy A Mariuzza
Journal:  J Exp Med       Date:  2011-03-21       Impact factor: 14.307

7.  High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity.

Authors:  R C Lynn; Y Feng; K Schutsky; M Poussin; A Kalota; D S Dimitrov; D J Powell
Journal:  Leukemia       Date:  2016-02-22       Impact factor: 11.528

8.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

Authors:  Cameron S Brandt; Myriam Baratin; Eugene C Yi; Jacob Kennedy; Zeren Gao; Brian Fox; Betty Haldeman; Craig D Ostrander; Tomonori Kaifu; Christian Chabannon; Alessandro Moretta; Robert West; Wenfeng Xu; Eric Vivier; Steven D Levin
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

9.  Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production.

Authors:  Maryam Salimi; Luzheng Xue; Helen Jolin; Clare Hardman; David J Cousins; Andrew N J McKenzie; Graham S Ogg
Journal:  J Immunol       Date:  2015-11-18       Impact factor: 5.422

10.  Hepatitis B viral replication influences the expression of natural killer cell ligands.

Authors:  Lemonica Koumbi; Teresa Pollicino; Giovanni Raimondo; Naveenta Kumar; Peter Karayiannis; Salim I Khakoo
Journal:  Ann Gastroenterol       Date:  2016-04-25
View more
  6 in total

1.  Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.

Authors:  Portia L Thomas; Sarah M Groves; Yun-Kai Zhang; Jia Li; Paula Gonzalez-Ericsson; Shamilene Sivagnanam; Courtney B Betts; Hua-Chang Chen; Qi Liu; Cindy Lowe; Heidi Chen; Kelli L Boyd; Prasad R Kopparapu; Yingjun Yan; Lisa M Coussens; Vito Quaranta; Darren R Tyson; Wade Iams; Christine M Lovly
Journal:  J Thorac Oncol       Date:  2021-04-08       Impact factor: 20.121

Review 2.  Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer.

Authors:  Matthias Peipp; Katja Klausz; Ammelie Svea Boje; Tobias Zeller; Stefan Zielonka; Christian Kellner
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

Review 3.  The Natural Cytotoxicity Receptors in Health and Disease.

Authors:  Alexander David Barrow; Claudia Jane Martin; Marco Colonna
Journal:  Front Immunol       Date:  2019-05-07       Impact factor: 7.561

4.  Engineering a natural ligand-based CAR: directed evolution of the stress-receptor NKp30.

Authors:  Savannah E Butler; Rachel A Brog; Cheryl H Chang; Charles L Sentman; Yina H Huang; Margaret E Ackerman
Journal:  Cancer Immunol Immunother       Date:  2021-05-27       Impact factor: 6.968

Review 5.  Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer.

Authors:  J Obajdin; D M Davies; J Maher
Journal:  Clin Exp Immunol       Date:  2020-07-25       Impact factor: 4.330

Review 6.  Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies.

Authors:  Rebecca C Abbott; Ryan S Cross; Misty R Jenkins
Journal:  Int J Mol Sci       Date:  2020-01-14       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.